Related Experiment Video
Updated: Apr 23, 2026
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Progress in lipid-based nanoparticles for cancer therapy
Sarina Grinberg1, Charles Linder2, Eliahu Heldman3
1Department of Chemistry, Ben-Gurion University of the Negev, Israel.
Abstract:
Most conventional cancer therapeutics gain limited access to many types of tumors while having considerable adverse effects, resulting in low therapeutic efficacy and high toxicity. Therefore, research has now focused on the development of novel drug delivery systems (DDS) with the goal of maintaining high therapeutic drug levels at malignant cells and as low as possible drug levels in other cells. The introduction of nanotechnology has addressed some of these problems and opened up new avenues for improved cancer therapy. The design of nanoparticles for DDS takes into consideration issues such as targeting, controlled drug release and enhanced penetration via biological barriers. In this review we describe the design principles of targeted DDS for cancer therapy and the types of nanoparticles that are under development. Emphasis is put on lipid-based nanoparticles, particularly bolaamphiphilic vesicles that have tremendous potential in delivering therapeutic and diagnostic agents to specific cells following systemic administration.
Insights
Novel nanotechnology-based drug delivery systems (DDS) offer improved cancer therapy by targeting tumors and reducing side effects. Lipid-based nanoparticles, especially bolaamphiphilic vesicles, show great promise for delivering therapeutic agents.
Area of Science:
- Nanomedicine
- Biotechnology
- Materials Science
Background:
- Conventional cancer therapeutics exhibit limited tumor penetration and significant adverse effects, leading to low efficacy and high toxicity.
- Novel drug delivery systems (DDS) aim to optimize drug concentration at malignant sites while minimizing systemic exposure.
- Nanotechnology presents innovative solutions for overcoming challenges in cancer therapy.
Purpose of the Study:
- To review the design principles of targeted DDS for cancer therapy.
- To explore various types of nanoparticles currently under development for cancer treatment.
- To highlight the potential of lipid-based nanoparticles, specifically bolaamphiphilic vesicles, in targeted drug and diagnostic agent delivery.
Main Methods:
- Review of current literature on targeted drug delivery systems in cancer therapy.
- Analysis of nanoparticle design considerations including targeting, controlled release, and barrier penetration.
- Focus on lipid-based nanoparticles and bolaamphiphilic vesicles for systemic administration.
Main Results:
- Nanoparticle-based DDS can enhance drug accumulation in tumors and reduce toxicity.
- Design principles focus on achieving specific targeting, controlled drug release kinetics, and improved passage through biological barriers.
- Bolaamphiphilic vesicles demonstrate significant potential for targeted delivery of therapeutic and diagnostic agents.
Conclusions:
- Targeted DDS utilizing nanotechnology offer a promising strategy to improve cancer treatment efficacy and reduce patient toxicity.
- Lipid-based nanoparticles, particularly bolaamphiphilic vesicles, are key candidates for advanced cancer nanomedicine.
- Further development of these systems could revolutionize the delivery of both therapeutic and diagnostic agents in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers